Inhibikase Therapeutics (NASDAQ:IKT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Inhibikase Therapeutics (NYSE:IKT) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $6.00 price target on the stock.
Inhibikase Therapeutics (NYSE:IKT) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at
Wall Str